← Back to Search

ATI for HIV Cure

N/A

Waitlist Available

Led By Andrew Badley, MD

Research Sponsored by Mayo Clinic

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age ≥ 18 years

Undetectable plasma HIV-1 RNA and undetectable proviral DNA on suppressive antiretroviral therapy on at least two consecutive measures for at least 6 months

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 38 weeks

Awards & highlights

Study Summary

This trial is testing if people with HIV can be cured of the infection by stopping antiretroviral therapy (ART) and closely monitoring them for infection reactivation.

Who is the study for?

Adults over 18 with HIV, potentially cured after routine care, are eligible. They must have undetectable HIV RNA and proviral DNA for at least 6 months on therapy. Participants should use barrier contraception or abstain from sex during the trial. Pregnant or nursing women and those not using contraceptives are excluded.Check my eligibility

What is being tested?

The study tests if patients can be considered cured of HIV by stopping their antiretroviral therapy under medical supervision to see if the infection reactivates.See study design

What are the potential side effects?

Stopping HIV medication may lead to viral rebound, immune system weakening, and potential reactivation of dormant infections. Close monitoring is essential to manage any adverse effects promptly.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

My HIV is undetectable and I've been on treatment for at least 6 months.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 38 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~38 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 38 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Time to virologic rebound

Secondary outcome measures

Time to HIV-1 RNA ≥ 100 copies/ml

Time to HIV-1 RNA ≥ 20 copies/ml

Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment interruptionExperimental Treatment1 Intervention

Antiretroviral therapy will be discontinued under close laboratory monitoring and clinical supervision.

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor

3,207 Previous Clinical Trials

3,766,850 Total Patients Enrolled

Andrew Badley, MDPrincipal InvestigatorMayo Clinic

1 Previous Clinical Trials

44 Total Patients Enrolled

Media Library

Analytic treatment interruption (NA) Clinical Trial Eligibility Overview. Trial Name: NCT02437526 — N/A

HIV/AIDS Research Study Groups: Treatment interruption

HIV/AIDS Clinical Trial 2023: Analytic treatment interruption Highlights & Side Effects. Trial Name: NCT02437526 — N/A

Analytic treatment interruption (NA) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02437526 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any vacancies available for participants in this research?

"Based on what is available on clinicaltrials.gov, no more patients are being recruited for this trial which was initially posted in May 2015 and last edited at the end of April 2022. However, there are currently 240 other active trials recruiting individuals."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Analytic Treatment Interruption (ATI) to Assess HIV Cure

Andrew D. Badley, M.D. 2015. "Analytic Treatment Interruption (ATI) to Assess HIV Cure". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02437526.